<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cartesian Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc</link>
<description>Latest news and press releases for Cartesian Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cartesian-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b94f78dffbe2df115654.webp</url>
<title>Cartesian Therapeutics, Inc.</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc</link>
</image>
<item>
<title>Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-to-participate-in-the-hc-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-to-participate-in-the-hc-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq</guid>
<pubDate>Tue, 12 May 2026 11:00:00 GMT</pubDate>
<description>FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events secti</description>
</item>
<item>
<title>Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 30 Apr 2026 11:00:00 GMT</pubDate>
<description>Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis Approximately $120.4 million cash, cash equivalents and restricted cash as of March 31, 2026, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FRED</description>
</item>
<item>
<title>Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
<description>Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AUROR</description>
</item>
<item>
<title>Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-highlights-recent-progress-130400047</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-highlights-recent-progress-130400047</guid>
<pubDate>Fri, 09 Jan 2026 13:04:00 GMT</pubDate>
<description>Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FR</description>
</item>
<item>
<title>Cartesian Therapeutics Announces New Employment Inducement Grants</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-employment-inducement-120500895</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-employment-inducement-120500895</guid>
<pubDate>Tue, 06 Jan 2026 12:05:00 GMT</pubDate>
<description>FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...</description>
</item>
<item>
<title>Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-appointment-adrian-210500184</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-appointment-adrian-210500184</guid>
<pubDate>Thu, 18 Dec 2025 21:05:00 GMT</pubDate>
<description>FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science a</description>
</item>
<item>
<title>Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-strong-efficacy-210500131</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-strong-efficacy-210500131</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy Myositis seamless adaptive clinical trial design provides potential opportunity for a si</description>
</item>
<item>
<title>Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-third-quarter-120000673</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-third-quarter-120000673</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected by end of year Approximately $145.1 million cash, cash equivalents and restricted cash as of September 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 A</description>
</item>
<item>
<title>Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-carsten-brunn-110000622</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-carsten-brunn-110000622</guid>
<pubDate>Thu, 30 Oct 2025 11:00:00 GMT</pubDate>
<description>FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company’s President and Chief Executive Officer and as a member of the Board, will succeed Carrie S. Cox, who is stepping down to focus on oth</description>
</item>
<item>
<title>Cartesian Therapeutics Announces New Employment Inducement Grant</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-employment-inducement-110500777</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-employment-inducement-110500777</guid>
<pubDate>Fri, 03 Oct 2025 11:05:00 GMT</pubDate>
<description>FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On October 2, 2025, the Company issued to this employee an option to purchase an aggregate of 9,700 shares of the Company’s common stock with an exercise price of $10.34, the closing trading price of the Company’s common stock o</description>
</item>
<item>
<title>Cartesian Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-participate-upcoming-investor-110000423</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-participate-upcoming-investor-110000423</guid>
<pubDate>Thu, 28 Aug 2025 11:00:00 GMT</pubDate>
<description>FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025A fireside chat at Morgan Stanley’s 23rd Annual Healthcare Conference at 4:05 p</description>
</item>
<item>
<title>Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-second-quarter-110000607</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-second-quarter-110000607</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $162.1 million cash, cash equivalents and restricted cash as of June 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., Aug.</description>
</item>
<item>
<title>Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-first-participant-110000174</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-first-participant-110000174</guid>
<pubDate>Fri, 30 May 2025 11:00:00 GMT</pubDate>
<description>FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product c</description>
</item>
<item>
<title>Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-participate-h-c-110000392</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-participate-h-c-110000392</guid>
<pubDate>Tue, 13 May 2025 11:00:00 GMT</pubDate>
<description>FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of</description>
</item>
<item>
<title>Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-first-quarter-110000909</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-first-quarter-110000909</guid>
<pubDate>Thu, 08 May 2025 11:00:00 GMT</pubDate>
<description>Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $182.1 million cash, cash equivalents and restricted cash as of March 31, 2025</description>
</item>
<item>
<title>Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-descartes-08-observed-110000924</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-descartes-08-observed-110000924</guid>
<pubDate>Tue, 08 Apr 2025 11:00:00 GMT</pubDate>
<description>After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12 Safety profile consist</description>
</item>
<item>
<title>Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-participate-24th-annual-110000267</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-participate-24th-annual-110000267</guid>
<pubDate>Tue, 01 Apr 2025 11:00:00 GMT</pubDate>
<description>FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the Co</description>
</item>
<item>
<title>Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-full-2024-110000437</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-reports-full-2024-110000437</guid>
<pubDate>Thu, 13 Mar 2025 11:00:00 GMT</pubDate>
<description>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout in 2H25 Company expects to initiate Phase 2 pediatric basket trial of Decartes-08 in select autoimmune indications in 2H25 Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $214.3</description>
</item>
<item>
<title>Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-fda-special-protocol-assessment-agreement-for-phase-3-aurora-trial-of-descartes-08-in-myasthenia-gravis</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-fda-special-protocol-assessment-agreement-for-phase-3-aurora-trial-of-descartes-08-in-myasthenia-gravis</guid>
<pubDate>Mon, 27 Jan 2025 05:00:00 GMT</pubDate>
<description>Trial on track to commence in 1H25 FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a</description>
</item>
<item>
<title>Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial</title>
<link>https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-positive-updated-results-from-phase-2b-trial-of-descartes-08-in-participants-with-myasthenia-gravis-and-outlines-design-of-planned-phase-3-trial</link>
<guid isPermaLink="true">https://6ix.com/company/cartesian-therapeutics-inc/news/cartesian-therapeutics-announces-positive-updated-results-from-phase-2b-trial-of-descartes-08-in-participants-with-myasthenia-gravis-and-outlines-design-of-planned-phase-3-trial</guid>
<pubDate>Tue, 03 Dec 2024 05:00:00 GMT</pubDate>
<description>Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis</description>
</item>
</channel>
</rss>